Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss)

Tumori

Volumn 100, Issue 6, 2014, Pages 612-619

  Ferrari, Stefano ^a   Meazza, Cristina ^b   Palmerini, Emanuela ^a   Tamburini, Angela ^c   Fagioli, Franca ^d   Cozza, Raffaele ^e   Ferraresi, Virginia ^f   Bisogno, Gianni ^g   Mascarin, Maurizio ^h   Cefalo, Graziella ^b   Manfrini, Marco ^a   Capanna, Rodolfo ^c   Biagini, Roberto ^f   Donati, Davide ^a   Picci, Piero ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

^d REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^e BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^f REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^g UNIVERSITY OF PADOVA   (Italy)

^h CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Methotrexate; Neoadjuvant chemotherapy; Osteosarcoma; Tumor necrosis

Indexed keywords

CISPLATIN; DOXORUBICIN; FOLINIC ACID; IFOSFAMIDE; METHOTREXATE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AMPUTATION; ARTICLE; BONE MARROW TOXICITY; BONE RESECTION; BONE SCINTISCANNING; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; ITALIAN (CITIZEN); MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NONMETASTATIC OSTEOSARCOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOPEDIC SURGERY; OSTEOSARCOMA; OVERALL SURVIVAL; PREOPERATIVE TREATMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); ROTATIONPLASTY; TREATMENT DURATION; TUMOR LOCALIZATION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BONE NEOPLASMS; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; ITALY; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; SURVIVAL; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHILD; CISPLATIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; ITALY; MALE; METHOTREXATE; NEOADJUVANT THERAPY; OSTEOSARCOMA; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84923302684     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/1778.19262     Document Type: Article

References (17)

1. Hogendoorn PC; ESMO/EUROBONET Working Group, Athanasou N, Bielack S, De Alava E, Dei Tos A P, Ferrari S, Gelderblom H, Grimer R, Hall KS, Hassan B, Hogendoorn PC, Jurgens H, Paulussen M, Rozeman L, Taminiau AH, Whelan J, Vanel D: Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21: 204-213, 2010.
2. Anninga JK, Gelderblom H, Fiocco M., Kroep JR, Taminiau AH, Hogendoorn PC, Egeler RM: Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer, 47: 2431-2445, 2011.
3. Ferrari S, Ruggieri P, Cefalo G., Tamburini A, Capanna R, Fagioli F., Comandone A, Bertulli R, Bisogno G., Palmerini E, Alberghini M, Parafioriti A., Linari A, Picci P, Bacci G: Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in non-metastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. J Clin Oncol, 30: 2112-2118, 2012.
4. Ferrari S, Bertoni F, Mercuri M., Picci P, Giacomini S, Longhi A., Bacci G: Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol, 12: 1145-1150, 2001.
5. Ferrari S, Perut F, Fagioli F., Brach Del Prever A, Meazza C, Parafioriti A, Picci P, Gambarotti M, Avnet S, Baldini N, Fais S: Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients' bed. J Transl Med, 11: 268, 2013.
6. Enneking WF, Dunham W, Gebhardt M., Malawar M, Pritchard DJ: A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Rel Res, 286: 241-245, 1993.
7. Picci P, Bacci G, Campanacci M., Gasparini M, Pilotti S, Cerasoli S., Bertoni F, Guerra A, Capanna R., Albisinni U: Histologic evaluation of necrosis induced by chemotherapy. Regional mapping of viable and nonviable tissue. Cancer, 56: 1515-1521, 1985.
8. Mobley A, Linder SK, Braeuer R, Ellis L.M., Zwelling L: A survey on data reproducibility in cancer research provides insights into our limited ability to translate findings from the laboratory to the clinic. PLoS ONE, 8: e63221, 2013.
9. Bacci G, Picci P, Ruggieri P., Mercuri M, Avella M, Capanna R., Brach Del Prever A, Mancini A, Gherlinzoni F, Padovani G: Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer, 65: 2539-2553, 1990.
10. Winkler K, Beron G, Delling G., Heise U, Kabisch H, Purfürst C, Berger J., Ritter J, Jürgens H, Gerein V: Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol, 6: 329-337, 1988.
11. Kempf-Bielack B., Flege S, Delling G., Jurgens H, Kevric M, Kotz R., Exner GU, Helmke K, von Hochstetter AR, Kuhne T, Jundt G, Lang S., Maas R, Reichardt P, Werner M., Zoubek A, Bielack S: Results of the prospective Cooperative Osteosarcoma Study Group COSS-96 of intensive, risk-stratified chemotherapy for osteosarcoma. Abstract book of the 40th Annual SIOP Conference 2008, p 63, abstract O. 158, 2008.
12. Whelan JS, Jinks RC, McTiernan A, Sydes M.R., Hook JM, Trani L, Uscinska B, Bramwell V., Lewis IJ, Nooij MA, van Glabbeke M, Grimer RJ, Hogendoorn P.C., Taminiau AH, Gelderblom H: Survival from high-grade localized extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. Ann Oncol, 23: 1607-1616, 2012.
13. National Cancer Institute: PDQ® osteosarcoma and malignant fibrous histiocytoma of bone treatment. National Cancer Institute, Bethesda, MD, USA. Available at http://cancer.gov/cancertopics/pdq/treatment/osteosarcoma/HealthProfessional/page4. Accessed 13 August 2014.
14. Fuchs N, Bielack SS, Epler D, Bieling P., Delling G, Körholz D, Graf N., Heise U, Jürgens H, Kotz R., Salzer-Kuntschik M, Weinel P, Werner M., Winkler K: Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol, 9: 893-899, 1998.
15. Meyers PA, Schwartz CL, Krailo M.D., Healey JH, Bernstein ML, Betcher D, Ferguson W.S., Gebhardt MC, Goorin AM, Harris M, Kleinerman E., Link M P, Nadel H, Nieder M., Siegal G P, Weiner MA, Wells R.J., Womer RB, Grier HE: Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children's Oncology Group. J Clin Oncol, 26: 633-638, 2008.
16. Smeland S, Bruland OS, Hjorth L, Brosjö O, Bjerkehagen B, Osterlundh G, Jakobson A, Hall KS, Monge OR, Björk O, Alvegaard TA: Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years. Acta Orthop, 82: 211-216, 2011.
17. Ferrari S, Smeland S, Mercuri M., Bertoni F, Longhi A, Ruggieri P., Alvegard TA, Picci P, Capanna R, Bernini G., Müller C, Tienghi A., Wiebe T, Comandone A, Böhling T, Del Prever AB, Brosjö O, Bacci G, Saeter G: Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol, 23: 8845-8852, 2005.